SALARIUS PHARMACEUTICALS INC (SLRX) Fundamental Analysis & Valuation

NASDAQ:SLRX • US79400X5032

Current stock price

0.84 USD
+0.19 (+29.23%)
At close:
0.835 USD
-0.01 (-0.6%)
After Hours:

This SLRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SLRX Profitability Analysis

1.1 Basic Checks

  • SLRX had negative earnings in the past year.
  • SLRX had a negative operating cash flow in the past year.
  • SLRX had negative earnings in each of the past 5 years.
  • In the past 5 years SLRX always reported negative operating cash flow.
SLRX Yearly Net Income VS EBIT VS OCF VS FCFSLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -82.08%, SLRX is doing worse than 68.68% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -117.81%, SLRX is in line with its industry, outperforming 41.51% of the companies in the same industry.
Industry RankSector Rank
ROA -82.08%
ROE -117.81%
ROIC N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
SLRX Yearly ROA, ROE, ROICSLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • SLRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLRX Yearly Profit, Operating, Gross MarginsSLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. SLRX Health Analysis

2.1 Basic Checks

  • SLRX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SLRX has been increased compared to 5 years ago.
  • Compared to 1 year ago, SLRX has a worse debt to assets ratio.
SLRX Yearly Shares OutstandingSLRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K
SLRX Yearly Total Debt VS Total AssetsSLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • SLRX has an Altman-Z score of -19.94. This is a bad value and indicates that SLRX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -19.94, SLRX is doing worse than 82.45% of the companies in the same industry.
  • There is no outstanding debt for SLRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.94
ROIC/WACCN/A
WACCN/A
SLRX Yearly LT Debt VS Equity VS FCFSLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 3.28 indicates that SLRX has no problem at all paying its short term obligations.
  • SLRX has a worse Current ratio (3.28) than 61.13% of its industry peers.
  • A Quick Ratio of 3.28 indicates that SLRX has no problem at all paying its short term obligations.
  • SLRX has a Quick ratio (3.28) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.28
Quick Ratio 3.28
SLRX Yearly Current Assets VS Current LiabilitesSLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SLRX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 68.10% over the past year.
EPS 1Y (TTM)68.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SLRX will show a decrease in Earnings Per Share. The EPS will decrease by -3.17% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-126.98%
EPS Next 2Y-3.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLRX Yearly Revenue VS EstimatesSLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2026 2M 4M 6M 8M 10M
SLRX Yearly EPS VS EstimatesSLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 -50K -100K -150K

More info and screens

Find the best growth stocksShow best growing peers

0

4. SLRX Valuation Analysis

4.1 Price/Earnings Ratio

  • SLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SLRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLRX Price Earnings VS Forward Price EarningsSLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLRX Per share dataSLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

  • A cheap valuation may be justified as SLRX's earnings are expected to decrease with -3.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.17%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SLRX Dividend Analysis

5.1 Amount

  • No dividends for SLRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SLRX Fundamentals: All Metrics, Ratios and Statistics

SALARIUS PHARMACEUTICALS INC

NASDAQ:SLRX (1/7/2026, 8:00:02 PM)

After market: 0.835 -0.01 (-0.6%)

0.84

+0.19 (+29.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-19
Inst OwnersN/A
Inst Owner Change14652%
Ins OwnersN/A
Ins Owner Change4.16%
Market Cap4.92M
Revenue(TTM)N/A
Net Income(TTM)-5.00M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)-39.18
EYN/A
EPS(NY)-4.39
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0
BVpS0.72
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.08%
ROE -117.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.28
Quick Ratio 3.28
Altman-Z -19.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.05%
EPS Next Y-126.98%
EPS Next 2Y-3.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.38%
OCF growth 3YN/A
OCF growth 5YN/A

SALARIUS PHARMACEUTICALS INC / SLRX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SALARIUS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 1 / 10 to SLRX.


What is the valuation status for SLRX stock?

ChartMill assigns a valuation rating of 0 / 10 to SALARIUS PHARMACEUTICALS INC (SLRX). This can be considered as Overvalued.


What is the profitability of SLRX stock?

SALARIUS PHARMACEUTICALS INC (SLRX) has a profitability rating of 0 / 10.


How sustainable is the dividend of SALARIUS PHARMACEUTICALS INC (SLRX) stock?

The dividend rating of SALARIUS PHARMACEUTICALS INC (SLRX) is 0 / 10 and the dividend payout ratio is 0%.